Companies /Healthcare

Abivax

NASDAQ: ABVX Biotechnology

ABVX at a Glance

Valuation
Market cap
$7.1B
Profitability
Revenue (TTM)
$4.7M
EPS (TTM)
$-6.08
Price
52-week range
$70 – $149
Street target
$163.58
Earnings
Next report
Dec 21, 2026

Headquartered in 7-11 Boulevard Haussmann, Paris Fiscal year ends December NASDAQ: ABVX abivax.com

About Abivax SA

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis (UC) and in Phase 2b trials for Crohn's disease (CD). Abivax is listed on both Euronext Paris and Nasdaq. The company is currently pre-revenue, investing heavily in late-stage clinical development and pre-commercial infrastructure as it prepares for a planned NDA submission for obefazimod in UC by end of 2026. Abivax operates across France and the United States and maintains a debt-free balance sheet following the completion of its royalty certificate buy-back program. Updated

ABVX Coverage

Frequently Asked Questions

What does Abivax SA do?

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.

What is the ABVX stock price target?

The Wall Street consensus 12-month price target for ABVX is $163.58.